Session 6 part 1

601 views
486 views

Published on

Published in: Business, Technology
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
601
On SlideShare
0
From Embeds
0
Number of Embeds
4
Actions
Shares
0
Downloads
8
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Session 6 part 1

  1. 1. S E S S IO N V IR e s o u r c e s a n d S e r v ic e s F o rA d v a n c in g D r u g D is c o v e r yC h a ir — S u z a n a P e t a n c e s k a , P h D, Na t io n a l I n s t it u t e o nA g in g S e s s io n O v e r v ie wSuzana Petanceska, PhD, National Institute on Aging A n A c a d e m ic P e r s p e c t iv e o n D r u g D is c o v e r yS e r v ic e s : C e n t e r s & C R O sMarcie Glicksman, PhD, Harvard NeuroDiscovery Center A D r u g D is c o v e r y S e r v ic e s P e r s p e c t iv e o n A c a d e m icC o lla b o r a t io n sBruce Molino, PhD, Albany Molecular Research, Inc. P r e c lin ic a l T h e r a p e u t ic s D e v e lo p m e n t f o rN e u r o lo g ic a l D is o r d e r s : F u n d in g & R e s o u r c e sRebecca Farkas, PhD, National Institute of Neurological Disorders and Stroke
  2. 2. Laboratory for Drug Discovery in Neurodegeneration (LDDN)“Academic Models of Drug Discovery: Services and Utilizing CROs” Marcie Glicksman 6th Annual Drug Discovery Course February 13-14, 2012
  3. 3. Outline> Why outsource?> Academic Resources> Contract Research Organizations Disclaimer: this will in no way be complete! Harvard NeuroDiscovery Center
  4. 4. Why Outsource?> Lack of internal resources> Lack of expertise> Lack of proper equipment – Chemistry scale up – Robotics – Chemical libraries> Flexibility – Can accommodate needs when you have them Harvard NeuroDiscovery Center
  5. 5. What resources do you need? Discovery PreClinical Clinical Approval•Bioinformatics •Pharmacokinetics •API supply •NDA filing•Target ID •ADME studies •Scale-up •Approval•Target validation •Toxicology •Stability trials •Launch•Assay development •Pharmacology •Formulation •Manufacturing•Virtual screening •Analytical methods •Patient access•HTS screening •Route development •Clinical trials (I-IV)•Reference compounds •Non-GMP scale-up •Drug product•Compound libraries •cGMP scale-up•Medicinal Chemistry •Pre-formulation•secondary assays•In vivo studies•Patent writing Harvard NeuroDiscovery Center
  6. 6. What to outsource?> Outsourcing is a HUGE industry, est. $7-8 billion market.> Every segment of the drug discovery process can be outsourced.> What are your core competencies?> What resources do you have?> Gold standards – HERG channel activity = Chantest – Preclinical toxicity studies – GLP studies – GMP studies Harvard NeuroDiscovery Center
  7. 7. Academic Resources> More than 72 Screening centers around the world! – You can find a directory here: http://www.slas.org/screeningFacilities/facilityList.cfm> Medicinal chemistry centers – Sometimes paired with screening centers – New Directory http://www.slas.org/mcFacilities/facilityList.cfm> In vivo Pharmacology – Pharmacy schools> Animal models – Foundations for specific disease area • e.g. MJ Fox Foundation, ADDF, Families of SMA – Psychogenics – JSW Research – SRI – Academic labs> GMP Synthesis Harvard NeuroDiscovery Center
  8. 8. Internet Resources> Equipment – LabAutopedia • Topics related to automation, tools and technologies • http://www.labautopedia.com/mw/index.php/Main_Page – LabMan blog • http://www.slas.org/blog/index.cfm> Assay technologies – Assay Guidance Manual • http://spotlite.nih.gov/assay/index.php/Table_of_Contents> Web courses and forums – Society for Laboratory Automation and Screening (SLAS) • Webinars, short courses – AAAS • webinars – Discussion groups (LinkedIn, Facebook, YouTube)> Local State Biotechnology Council – e.g. MBC sponsors regular programs Harvard NeuroDiscovery Center
  9. 9. LabAutopedia> Automation – HTS – Genomics> Tools and Technologies> Data collection and processing> Conference posters> Science books http://www.labautopedia.com/mw/index.php/Portal:Contents 03/26/12 Harvard NeuroDiscovery Center
  10. 10. Assay Guidance Manual> All types of assays> Details on strengths and weaknesses> Options for target types http://spotlite.nih.gov/assay/index.php/Table_of_Contents 03/26/12 Harvard NeuroDiscovery Center
  11. 11. Example: Harvard ICCB-Longwood Institute of Chemistry and Cell Biology> Core facility for investigator initiated screening> Mainly for Harvard community> Small molecules and RNAi libraries> Collaborators perform their own assay development, perform their own assays, provide all reagents including plates> Staff maintain and run robotics> Recharge costs> Take your compounds with you> Simple IP Harvard NeuroDiscovery Center
  12. 12. Model at LDDN: Collaborative Interactions Drive Discovery> For general academic community> Small molecule libraries skewed with properties more “drug-like” and likely BBB penetrable (size,PSA, LogP, Lipinski guidelines)> LDDN or post-doc develops assay and LDDN runs automation> LDDN provides medicinal chemistry> Joint grant submission> Joint IP/ownership> Joint licensing LDDN Staff Collaborating (12) Lab Harvard NeuroDiscovery Center
  13. 13. Types of Contract Research Organizations> Fully integrated CRO vs. specialist – Big-box (one-stop-shop) vs. boutique – Covance, Ricerca – Cyprotex, Absorption Systems, Wolfe Labs, AMRI> Location US, Europe, India, China> High, medium, low cost vendors> The staff – ratio of PhD-to-MS/BS techs, & years experience – Most important is that they have experience relevant to your project – Take advantage of their experience Harvard NeuroDiscovery Center
  14. 14. Types of CRO Models> FFS (Fee For Service) – Client drives the science – Competitive RFQs (request for quote) – Protocols worked out or easier chemistry – Intermediates,monomers, templates – Per compound rate> FTE (Full Time Equivalent) – Client drives the science – With trusted partners – Difficult or speculative chemistry – Reference compounds – Large queues at low cost CROs – Do you have enough work for FTE rate?> Collaborations – CRO helps drive part or all of the science – May be FTE based – May include risk sharing> Reduced fee> Equity> Milestone payments Harvard NeuroDiscovery Center
  15. 15. What LDDN Outsources> Protein purification (e.g. Blue Sky)> In vitro ADME (e.g. Cyprotex) – Microsomal stability – solubility> Pharmacokinetics (e.g. Absorption Systems)> Profiling – Kinome (e.g. Carna Biosciences, Nanosyn) – Side effect profiling (e.g. MDS Pharma, Cerep, Caliper) – mechanism> Supplemental chemistry (e.g. Aberjona)> In vivo efficacy models – Academic labs Harvard NeuroDiscovery Center
  16. 16. Recommendations> Develop a list of CROs with overlapping capabilities> Give a small pilot project to a CRO before more commitment. – Some go as far as sending the same project to more than one CRO.> Make sure you get updates> Make sure you get reports that are satisfactory and you have agreed ahead of time on what these reports will look like. – Contain supporting documentation – Contain raw values> Confidentiality agreements are standard – Is the CRO covered by US/WTO patent laws? – Proprietary process and product needs to be defined> Establish a relationship with CROs Harvard NeuroDiscovery Center
  17. 17. Equipment/Technology Partnerships> What academics can offer vendors – As a central facility, many scientists gain exposure to the instrument and technology – Act as a “Demo” site – Novel applications – Collaborations – Data sharing (no proprietary targets, no long approval process) D – Publications> What vendors can offer academics – Price discounts – Collaborations – Access to new technology early 03/26/12 Harvard NeuroDiscovery Center
  18. 18. Summary> Lots of resources out there!> Use resources that are outside of your expertise> Talk with others for recommendations> Try a pilot project with a new outsourcing partner> Establish a relationship> Make sure you discuss what your expectations are Harvard NeuroDiscovery Center
  19. 19. Thank YOU, for your attention!
  20. 20. A Drug Discovery ServicesPerspective on AcademicCollaborations6th Drug Discovery For NeurodegenerationConference: An Intensive Course on TranslatingResearch into DrugsFebruary 12-14, 2012Bruce Molino, Ph.D.Senior Director, AMRI Medicinal Chemistry
  21. 21. AMRI Global Integrated Drug Discovery, Development &Manufacturing ServicesAs a global leader in drug discovery, AMRI provides valuable contract discovery,development, and manufacturing services to advance our clients’ goals.AMRI advantages include: • Comprehensive in vitro biology, in vitro ADMET and chemistry capability from lead generation to advanced development to manufacturing • Substantial capacity located at multiple facilities throughout the world • Integrated services providing a seamless product to the client • Cost effective outsourcing solutions with flexible business models
  22. 22. Overview •What are the R&D outsourcing needs of Academic laboratories? •What Drug Discovery Services are available from CROs? •How do you identify the best CRO to meet your needs? •Outsourcing cost?
  23. 23. Role of US Academia in Drug Discovery• “Academic institutions and their investigators traditionally play a key role in identifying novel potential targets but do not participate in later stages of the drug discovery process”• Survey of ~80 academic drug discovery centers indicated that on average 49% of targets being investigated are based on unique discoveries that had little validation in the literature• “Drug companies cannot afford the risk of investing on a novel approach without strong validation that the new approach is viable”• Need to do a better job of translation of these early innovations to the proof of concept and into human clinical trialsP. Jeffrey Conn, “Translation of Research Across Disciplines to Impact Patient Care” Vanderbilt Center for Neuroscience Drug Discovery, http://www.vcndd.com/presentations/S. Frye, M. Crosby, T. Edwards, R. Juliano Nature Rev Drug Discov. 10, 409, 2011
  24. 24. CROs work with Non-Profits & GovernmentAgencies to ‘Bridge the Gap’Albany, NY (August 18, 2011) – AMRI (NASDAQ: AMRI) today announced itreceived a federal contract award from the National Institutes of Health (NIH) /National Institute of Neurological Disorders and Stroke (NINDS) to providechemistry and other drug discovery technologies in support of NINDS MedicinalChemistry for Neurotherapeutics Program (MCNP), part of the NIH BlueprintNeurotherapeutics Network. AMRI has been collaborating with NINDS since 2005on novel treatments for spinal muscular atrophy, a degenerative neuromusculardisease.
  25. 25. Areas that AD can Benefit from OutsourcingMany academic programs are in early stages of Drug Discovery,Hit Generation• Validated ‘Hits’ identified from biological screeningLead Generation• Progress through ‘Hit-to-Lead’ stage to Lead Compound SeriesLead Optimization• Progress Lead Series to Pre-Clinical Development Candidateand seek to translate innovative approaches to useful therapies.
  26. 26. Hit Generation/ExploratoryPrerequisites•Target-based or phenotypic-based screen•Validated screening assay•Screening strategy – assay format/compounds for testingOutput/Goal of this stage:•Hit finding•Hit validation•Hit selection•Determine which screening hits have the best chance ofbecoming a Lead Chemical Series
  27. 27. Hit Validation – Important ConsiderationsPay attention to the basics in hit validation•Confirm bioassay results•Low cytotoxicity•Confirm integrity of test compounds, purity, chemical structure•CADD – similarity searches, cheminformatic clustering, virtual screening,SBDD docking studies/pharmacophore model/virtual screen•Apply relevant filters – MW, clogP, tPSA, HBD, HBA, solubility•Identify frequent hitters, compounds with reactive functionalityHit Selection•Emerging S.A.R. from structurally similar analogues•Cellular proof-of-concept – functional activity•Freedom to operate in chemical space•Synthetic feasibility•DMPK properties
  28. 28. What can be outsourced? Artwork
  29. 29. In Vitro Biology Services

×